Isis Pharmaceuticals' Genetrove division and the R.W. Johnson Pharmaceutical Research Institute initiate antisense target validation program.(Brief Article): An article from: BIOTECH Patent News

This digital document is an article from BIOTECH Patent News, published by Biotech Patent News on August 1, 2000. The length of the article is 443 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Isis Pharmaceuticals' Genetrove division and the R.W. Johnson Pharmaceutical Research Institute initiate antisense target validation program.(Brief Article)
Publication:BIOTECH Patent News (Newsletter)
Date: August 1, 2000
Publisher: Biotech Patent News
Volume: 14 Issue: 8 Page: NA

Article Type: Brief Article

Distributed by Thomson Gale